GDRX GoodRx
- 4.638
- -0.022-0.47%
GoodRx News
Citi Maintains GoodRx(GDRX.US) With Buy Rating, Cuts Target Price to $7
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $8.5
A Quick Look at Today's Ratings for GoodRx(GDRX.US), With a Forecast Between $5 to $7
GoodRx Holdings Is Maintained at Overweight by Barclays
GoodRx Holdings Analyst Ratings
Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating, Announces Target Price $6.5
Barclays Maintains GoodRx(GDRX.US) With Buy Rating, Cuts Target Price to $6
A Quick Look at Today's Ratings for GoodRx(GDRX.US), With a Forecast Between $4.5 to $10
A Quick Look at Today's Ratings for GoodRx(GDRX.US), With a Forecast Between $4.5 to $10
Morgan Stanley Adjusts GoodRx Holdings' Price Target to $7 From $9.50, Keeps Equalweight Rating
GoodRx Holdings: Mixed Signals Prompt Hold Rating Amid Revenue Challenges and EBITDA Prospects
GoodRx Holdings Faces Sell Rating Amid PBM Pressure and Business Model Challenges
GoodRx Holdings (GDRX) Gets a Buy From Barclays
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $5
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $5
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings (GDRX) Receives a Buy From RBC Capital
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $16
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $16
Leerink Partners Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $12
Analysis
Price Target
No Data
No Data